Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
BABY's Cash to Debt is ranked higher than
97% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.28 vs. BABY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
BABY' s Cash to Debt Range Over the Past 10 Years
Min: 0.32  Med: 54.37 Max: No Debt
Current: No Debt
Equity to Asset 0.83
BABY's Equity to Asset is ranked higher than
84% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. BABY: 0.83 )
Ranked among companies with meaningful Equity to Asset only.
BABY' s Equity to Asset Range Over the Past 10 Years
Min: -1.79  Med: 0.83 Max: 0.94
Current: 0.83
-1.79
0.94
Interest Coverage 134.04
BABY's Interest Coverage is ranked higher than
65% of the 192 Companies
in the Global Medical Devices industry.

( Industry Median: 44.71 vs. BABY: 134.04 )
Ranked among companies with meaningful Interest Coverage only.
BABY' s Interest Coverage Range Over the Past 10 Years
Min: 4.92  Med: 67.71 Max: 151.91
Current: 134.04
4.92
151.91
F-Score: 8
Z-Score: 10.47
M-Score: -2.43
WACC vs ROIC
8.92%
12.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 13.73
BABY's Operating margin (%) is ranked higher than
81% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.61 vs. BABY: 13.73 )
Ranked among companies with meaningful Operating margin (%) only.
BABY' s Operating margin (%) Range Over the Past 10 Years
Min: -4.54  Med: 9.43 Max: 15.75
Current: 13.73
-4.54
15.75
Net-margin (%) 10.13
BABY's Net-margin (%) is ranked higher than
76% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. BABY: 10.13 )
Ranked among companies with meaningful Net-margin (%) only.
BABY' s Net-margin (%) Range Over the Past 10 Years
Min: -5.03  Med: 6.65 Max: 10.8
Current: 10.13
-5.03
10.8
ROE (%) 9.98
BABY's ROE (%) is ranked higher than
71% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.05 vs. BABY: 9.98 )
Ranked among companies with meaningful ROE (%) only.
BABY' s ROE (%) Range Over the Past 10 Years
Min: -4.48  Med: 6.32 Max: 10.21
Current: 9.98
-4.48
10.21
ROA (%) 8.16
BABY's ROA (%) is ranked higher than
79% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. BABY: 8.16 )
Ranked among companies with meaningful ROA (%) only.
BABY' s ROA (%) Range Over the Past 10 Years
Min: -3.62  Med: 4.80 Max: 8.3
Current: 8.16
-3.62
8.3
ROC (Joel Greenblatt) (%) 50.87
BABY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 4.07 vs. BABY: 50.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BABY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13.04  Med: 31.99 Max: 56.76
Current: 50.87
-13.04
56.76
Revenue Growth (3Y)(%) 4.90
BABY's Revenue Growth (3Y)(%) is ranked higher than
54% of the 236 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. BABY: 4.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BABY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.9  Med: 11.00 Max: 38.3
Current: 4.9
-61.9
38.3
EBITDA Growth (3Y)(%) 52.20
BABY's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 201 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. BABY: 52.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BABY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -12.1  Med: 30.40 Max: 168.5
Current: 52.2
-12.1
168.5
EPS Growth (3Y)(%) 106.30
BABY's EPS Growth (3Y)(%) is ranked higher than
95% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. BABY: 106.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BABY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -53.1  Med: -16.15 Max: 106.3
Current: 106.3
-53.1
106.3
» BABY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

BABY Guru Trades in Q2 2015

Ken Fisher 610,166 sh (+7.10%)
Diamond Hill Capital 878,320 sh (-0.39%)
Jim Simons 87,445 sh (-1.02%)
Joel Greenblatt 338,647 sh (-4.27%)
Paul Tudor Jones 7,156 sh (-58.24%)
» More
Q3 2015

BABY Guru Trades in Q3 2015

Diamond Hill Capital 958,306 sh (+9.11%)
Paul Tudor Jones Sold Out
Ken Fisher 601,141 sh (-1.48%)
Joel Greenblatt 331,210 sh (-2.20%)
Jim Simons 26,845 sh (-69.30%)
» More
Q4 2015

BABY Guru Trades in Q4 2015

Paul Tudor Jones 9,568 sh (New)
Jim Simons 138,245 sh (+414.97%)
Ken Fisher 595,274 sh (-0.98%)
Joel Greenblatt 180,922 sh (-45.38%)
Diamond Hill Capital 490,631 sh (-48.80%)
» More
Q1 2016

BABY Guru Trades in Q1 2016

Diamond Hill Capital 591,256 sh (+20.51%)
Paul Tudor Jones Sold Out
Ken Fisher 589,433 sh (-0.98%)
Joel Greenblatt 84,563 sh (-53.26%)
Jim Simons 56,945 sh (-58.81%)
» More
» Details

Insider Trades

Latest Guru Trades with BABY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:CYNO, OTCPK:DRWKF, NAS:CNMD, NAS:LDRH, NAS:ZLTQ, OTCPK:IOBCF, OTCPK:BSNRF, NYSE:GB, NAS:INGN, OTCPK:SKUNF, NAS:MDXG, NAS:OFIX, NAS:SPNC, NAS:VASC, OTCPK:CSRMF, OTCPK:MCRPF, NAS:KTWO, NAS:CSII, OTCPK:JIDG, NAS:HTWR » details
Traded in other countries:NM4.Germany,
Natus Medical Inc provides newborn care & neurology healthcare products & services used for screening, diagnosis, detection, treatment, monitoring & tracking of medical ailments in newborn care, epilepsy, sleep disorders, and balance & mobility disorders.

Natus Medical Inc was incorporated in California in May 1987 and reincorporated in Delaware in August 2000. The Company is a provider of newborn care and neurology healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders. The Company offers two product families: Neurology and Newborn Care. Neurology includes products for diagnostic electroencephalography (EEG), electromyography (EMG), diagnostic sleep analysis or polysomnography (PSG), intra-operative monitoring (IOM), and transcranial doppler ultrasound technology. Newborn Care includes products for newborn care including hearing screening, brain injury, thermoregulation, jaundice management, and various disposable products, as well as products for diagnostic hearing assessment for children through adult populations, and products to diagnose and assist in treating balance and mobility disorders. The Company is subject to inspection and market surveillance by the FDA to determine compliance with regulatory requirements.

Guru Investment Theses on Natus Medical Inc

Diamond Hill Capital Comments on Natus Medical Inc - Oct 17, 2014

Shares of medical device manufacturer Natus Medical, Inc. (BABY) increased after reporting strong quarterly earnings and raising its full-year 2014 earnings guidance. While the company has shown improvement in margins for some time, this was the best quarter of organic revenue growth for Natus in years.

From Diamond Hill Capital (Trades, Portfolio)'s Small Cap Fund Third Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Diamond Hill Capital Comments on Natus Medical Inc - Jun 26, 2014

Shares of infant medical device manufacturer Natus Medical, Inc. (BABY) rose as the company reported strong quarterly earnings, continued margin improvement, and a promising outlook for the year.



From Diamond Hill Capital's Small Cap Fund Commentary – First Quarter 2014.



Check out Diamond Hill Capital latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 31.31
BABY's P/E(ttm) is ranked lower than
56% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 26.80 vs. BABY: 31.31 )
Ranked among companies with meaningful P/E(ttm) only.
BABY' s P/E(ttm) Range Over the Past 10 Years
Min: 11.47  Med: 37.22 Max: 723.45
Current: 31.31
11.47
723.45
Forward P/E 23.15
BABY's Forward P/E is ranked higher than
56% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 23.53 vs. BABY: 23.15 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.31
BABY's PE(NRI) is ranked lower than
56% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 27.05 vs. BABY: 31.31 )
Ranked among companies with meaningful PE(NRI) only.
BABY' s PE(NRI) Range Over the Past 10 Years
Min: 11.43  Med: 37.15 Max: 699.33
Current: 31.31
11.43
699.33
Price/Owner Earnings (ttm) 51.65
BABY's Price/Owner Earnings (ttm) is ranked lower than
73% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 30.77 vs. BABY: 51.65 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BABY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 18.79  Med: 44.48 Max: 8415
Current: 51.65
18.79
8415
P/B 3.06
BABY's P/B is ranked lower than
51% of the 302 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. BABY: 3.06 )
Ranked among companies with meaningful P/B only.
BABY' s P/B Range Over the Past 10 Years
Min: 0.79  Med: 2.46 Max: 5.69
Current: 3.06
0.79
5.69
P/S 3.22
BABY's P/S is ranked lower than
51% of the 293 Companies
in the Global Medical Devices industry.

( Industry Median: 3.07 vs. BABY: 3.22 )
Ranked among companies with meaningful P/S only.
BABY' s P/S Range Over the Past 10 Years
Min: 0.95  Med: 2.53 Max: 8.45
Current: 3.22
0.95
8.45
PFCF 32.57
BABY's PFCF is ranked lower than
56% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 29.54 vs. BABY: 32.57 )
Ranked among companies with meaningful PFCF only.
BABY' s PFCF Range Over the Past 10 Years
Min: 12.62  Med: 32.72 Max: 1283.85
Current: 32.57
12.62
1283.85
POCF 28.20
BABY's POCF is ranked lower than
70% of the 130 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. BABY: 28.20 )
Ranked among companies with meaningful POCF only.
BABY' s POCF Range Over the Past 10 Years
Min: 10.17  Med: 28.35 Max: 106.24
Current: 28.2
10.17
106.24
EV-to-EBIT 21.37
BABY's EV-to-EBIT is ranked higher than
52% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 21.43 vs. BABY: 21.37 )
Ranked among companies with meaningful EV-to-EBIT only.
BABY' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.3  Med: 23.60 Max: 409.7
Current: 21.37
-29.3
409.7
EV-to-EBITDA 16.06
BABY's EV-to-EBITDA is ranked higher than
57% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 17.77 vs. BABY: 16.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
BABY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.2  Med: 17.55 Max: 5595.8
Current: 16.06
-82.2
5595.8
Shiller P/E 68.69
BABY's Shiller P/E is ranked lower than
68% of the 44 Companies
in the Global Medical Devices industry.

( Industry Median: 40.47 vs. BABY: 68.69 )
Ranked among companies with meaningful Shiller P/E only.
BABY' s Shiller P/E Range Over the Past 10 Years
Min: 53.07  Med: 85.83 Max: 127.78
Current: 68.69
53.07
127.78
Current Ratio 3.37
BABY's Current Ratio is ranked higher than
60% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. BABY: 3.37 )
Ranked among companies with meaningful Current Ratio only.
BABY' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.26 Max: 16.01
Current: 3.37
1.3
16.01
Quick Ratio 2.69
BABY's Quick Ratio is ranked higher than
62% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. BABY: 2.69 )
Ranked among companies with meaningful Quick Ratio only.
BABY' s Quick Ratio Range Over the Past 10 Years
Min: 0.91  Med: 2.55 Max: 15.09
Current: 2.69
0.91
15.09
Days Inventory 113.61
BABY's Days Inventory is ranked higher than
59% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 136.99 vs. BABY: 113.61 )
Ranked among companies with meaningful Days Inventory only.
BABY' s Days Inventory Range Over the Past 10 Years
Min: 82.54  Med: 116.99 Max: 132.6
Current: 113.61
82.54
132.6
Days Sales Outstanding 87.89
BABY's Days Sales Outstanding is ranked lower than
68% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.64 vs. BABY: 87.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
BABY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 81.74  Med: 87.02 Max: 112.34
Current: 87.89
81.74
112.34
Days Payable 48.67
BABY's Days Payable is ranked lower than
60% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 61.70 vs. BABY: 48.67 )
Ranked among companies with meaningful Days Payable only.
BABY' s Days Payable Range Over the Past 10 Years
Min: 44.18  Med: 76.53 Max: 92.2
Current: 48.67
44.18
92.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1200.00
BABY's Price/Net Cash is ranked lower than
99% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 16.61 vs. BABY: 1200.00 )
Ranked among companies with meaningful Price/Net Cash only.
BABY' s Price/Net Cash Range Over the Past 10 Years
Min: 1.4  Med: 4.28 Max: 1281
Current: 1200
1.4
1281
Price/Net Current Asset Value 8.05
BABY's Price/Net Current Asset Value is ranked lower than
56% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 6.73 vs. BABY: 8.05 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BABY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.09  Med: 6.46 Max: 2050
Current: 8.05
1.09
2050
Price/Tangible Book 6.08
BABY's Price/Tangible Book is ranked lower than
66% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 3.64 vs. BABY: 6.08 )
Ranked among companies with meaningful Price/Tangible Book only.
BABY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.02  Med: 4.91 Max: 64.5
Current: 6.08
1.02
64.5
Price/Projected FCF 2.06
BABY's Price/Projected FCF is ranked higher than
52% of the 126 Companies
in the Global Medical Devices industry.

( Industry Median: 2.02 vs. BABY: 2.06 )
Ranked among companies with meaningful Price/Projected FCF only.
BABY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.8  Med: 1.62 Max: 24.7
Current: 2.06
0.8
24.7
Price/Median PS Value 1.26
BABY's Price/Median PS Value is ranked lower than
62% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. BABY: 1.26 )
Ranked among companies with meaningful Price/Median PS Value only.
BABY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 0.98 Max: 2.87
Current: 1.26
0.12
2.87
Price/Peter Lynch Fair Value 8.26
BABY's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 2.19 vs. BABY: 8.26 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
BABY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.58  Med: 1.50 Max: 2.96
Current: 8.26
0.58
2.96
Price/Graham Number 2.91
BABY's Price/Graham Number is ranked lower than
57% of the 143 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. BABY: 2.91 )
Ranked among companies with meaningful Price/Graham Number only.
BABY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.2  Med: 3.10 Max: 33.61
Current: 2.91
1.2
33.61
Earnings Yield (Greenblatt) (%) 4.70
BABY's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.70 vs. BABY: 4.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BABY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 4.10 Max: 20
Current: 4.7
0.2
20
Forward Rate of Return (Yacktman) (%) 12.72
BABY's Forward Rate of Return (Yacktman) (%) is ranked higher than
68% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 7.13 vs. BABY: 12.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BABY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.5  Med: 2.60 Max: 75
Current: 12.72
-1.5
75

More Statistics

Revenue (TTM) (Mil) $373.8
EPS (TTM) $ 1.15
Beta0.98
Short Percentage of Float4.30%
52-Week Range $29.34 - 51.05
Shares Outstanding (Mil)33.12

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 380 390
EPS ($) 1.58 1.78
EPS w/o NRI ($) 1.58 1.78
EPS Growth Rate
(3Y to 5Y Estimate)
22.00%
» More Articles for BABY

Headlines

Articles On GuruFocus.com
Diamond Hill Small Cap Fund Q4 2014 Commentary Mar 17 2015 
Diamond Hill Small Cap Fund Third Quarter Letter Oct 25 2014 
Diamond Hill Capital Comments on Natus Medical Inc Oct 17 2014 
Diamond Hill Small Cap Fund Third Quarter 2014 Commentary Oct 17 2014 
Diamond Hill Capital Comments on Natus Medical Inc Jun 26 2014 
Diamond Hill Small Cap Fund Commentary – First Quarter 2014 Jun 25 2014 
Weekly CEO Sells Highlight: OCZ Technology Group Inc, Workday Inc, Gilead Sciences Inc, Natus Medica Dec 09 2013 
Natus Medical Inc. Reports Operating Results (10-Q) Nov 05 2010 
David Nierenberg’s Top Holdings: MOVE, ESIO, BABY, RSYS, HPY, SPN Aug 27 2010 
Natus Medical Inc. (BABY) VP Finance and CFO Steven J Murphy sells 1,814 Shares Aug 19 2010 

More From Other Websites
Natus Medical Expands Share Repurchase Program by $20M Jun 06 2016
Natus Reveals $20 Million Share Buyback Program Jun 03 2016
Natus Announces $20 Million Share Repurchase Program Jun 03 2016
NATUS MEDICAL INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 03 2016
Natus Medical, Inc. breached its 50 day moving average in a Bullish Manner : BABY-US : June 2, 2016 Jun 02 2016
Natus to Present at Jefferies 2016 Healthcare Conference Jun 01 2016
CASM: Zacks SCR Initiates Coverage of CAS Medical. May 24 2016
NATUS MEDICAL INC Financials May 11 2016
Lifshitz & Miller Law Firm Announces Investigation of Amaya, Inc., Chiasma, Inc., Intrexon... May 09 2016
Natus to Present at UBS Global Healthcare Conference May 09 2016
NATUS MEDICAL INC Files SEC form 10-Q, Quarterly Report May 04 2016
ATTENTION NATUS SHAREHOLDERS: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces... Apr 22 2016
Hagens Berman Investigates Natus Medical Inc.’s Guidance on Prepayments From the Venezuelan... Apr 22 2016
Natus Medical, Inc. :BABY-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 21 2016
Edited Transcript of BABY earnings conference call or presentation 20-Apr-16 3:00pm GMT Apr 20 2016
Natus Medical Inc Earnings Call scheduled for 11:00 am ET today Apr 20 2016
Q1 2016 Natus Medical Inc Earnings Release - Time Not Supplied Apr 20 2016
Natus Medical beats 1Q profit forecasts Apr 20 2016
Natus Medical beats 1Q profit forecasts Apr 20 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)